MedImmune Launches Enhanced Corporate Website
Gaithersburg, MD, July 23, 2001 -- MedImmune, Inc. (Nasdaq: MEDI) announced today that the new MedImmune, Inc. corporate website is now online. The new website, available at www.medimmune.com, was designed and developed to provide detailed and up-to-date information about the company, its products, the advancing research and development product pipeline. The new website also provides advanced navigational tools. The new website features:
- A detailed investors section, including stock price analysis tools, real-time SEC filings, corporate information, an on-line literature request function, and an email mechanism enabling investors to receive alerts whenever new information is posted to the site.
- Patient and healthcare provider-specific pages, including product specific information, frequently asked questions, and related resources.
- A research and development section with up-to-date information about products in development.
- A careers section, featuring a searchable employment database.
MedImmune.com was designed and developed by MedImmune in conjunction with Digital Wave Technologies, Inc. of Huntingdon Valley, PA (www.digitalwave.com).
MedImmune, Inc. is a biotechnology company focused on developing and marketing products that address medical needs in areas such as infectious disease, immune regulation and cancer. Headquartered in Gaithersburg, Maryland, MedImmune has manufacturing facilities in Frederick, Maryland and Nijmegen, the Netherlands.
This announcement may contain, in addition to historical information, certain forward-looking statements that involve risks and uncertainties. Such statements reflect management's current views and are based on certain assumptions. Actual results could differ materially from those currently anticipated as a result of a number of factors, including risks and uncertainties discussed in the company's filings with the U.S. Securities and Exchange Commission. The company is developing several products for potential future marketing. There can be no assurance that such development efforts will succeed, that such products will receive required regulatory clearance or that, even if such regulatory clearance were received, such products would ultimately achieve commercial success.